STAT3 and cancer: The combination of HLX22 and HLX02 resulted in a dramatic decrease in STAT3 (Y705), P70 S6 (T421/S424), and AKT1/2/3 (S473) phosphorylation levels, suggesting that HLX22 in combination with HLX02 could effectively inhibit cancer cell proliferation, induce cancer cell apoptosis and prevent drug resistance.